ID
45827
Beschreibung
Principal Investigator: Christine M. Albert, MD, MPH, Brigham and Women's Hospital, Boston, MA, USA MeSH: Atrial Fibrillation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001040 The Women's Genome Health Study (WGHS) is a prospective cohort comprised of over 25,000 initially healthy female health professionals enrolled in the Women's Health Study, which began in 1992-1994. All participants in WGHS provided baseline blood samples and extensive survey data. Women who reported atrial fibrillation during the course of the study were asked to report diagnoses of AF at baseline, 48 months, and then annually thereafter. Participants enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and to collect additional information. They were also asked for permission to review their medical records, particularly available ECGs, rhythm strips, 24-hour ECGs, and information on cardiac structure and function. For all deceased participants who reported AF during the trial and extended follow-up period, family members were contacted to obtain consent and additional relevant information. An end-point committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. The earliest date in the medical records when documentation was believed to have occurred was set as the date of onset of AF.
Link
Stichworte
Versionen (1)
- 29.07.23 29.07.23 - Simon Heim
Rechteinhaber
Christine M. Albert, MD, MPH, Brigham and Women's Hospital, Boston, MA, USA
Hochgeladen am
29. Juli 2023
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs001040 NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women
This sample attributes table includes body site where sample was collected, analyte type, tumor status, sequencing center, funding source, TOPMed phase, project, and study name.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent group information, subject aliases, and affection status for atrial fibrillation (AF).
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This sample attributes table includes body site where sample was collected, analyte type, tumor status, sequencing center, funding source, TOPMed phase, project, and study name.
- This subject phenotype data table includes subject's sex, race, atrial fibrillation (AF) status, age at enrollment, age at AF diagnosis, and cholesterol measurements (n=6 variables; LDL, HDL, triglycerides, total cholesterol and cholesterol lowering medication at baseline, and blood draw following 8 hr fast). Additional variables have been added: height, weight, BMI, waist/hip ratio, diabetes at baseline, age at menarche, uterine fibroids, age at menopause, diastolic and systolic blood pressure, blood test (n=9 variables; APOA1, APOB, creatinine, CRP, fibrinogen, HBA1C, homocysteine, ICAM, and LPA), principal components (n=10 variables), alcohol use, excercise, and smoking status.
Ähnliche Modelle
This sample attributes table includes body site where sample was collected, analyte type, tumor status, sequencing center, funding source, TOPMed phase, project, and study name.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent group information, subject aliases, and affection status for atrial fibrillation (AF).
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This sample attributes table includes body site where sample was collected, analyte type, tumor status, sequencing center, funding source, TOPMed phase, project, and study name.
- This subject phenotype data table includes subject's sex, race, atrial fibrillation (AF) status, age at enrollment, age at AF diagnosis, and cholesterol measurements (n=6 variables; LDL, HDL, triglycerides, total cholesterol and cholesterol lowering medication at baseline, and blood draw following 8 hr fast). Additional variables have been added: height, weight, BMI, waist/hip ratio, diabetes at baseline, age at menarche, uterine fibroids, age at menopause, diastolic and systolic blood pressure, blood test (n=9 variables; APOA1, APOB, creatinine, CRP, fibrinogen, HBA1C, homocysteine, ICAM, and LPA), principal components (n=10 variables), alcohol use, excercise, and smoking status.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C1561491 (UMLS CUI [1,2])
C0205390 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,2])